Healthcare
Live Price
Offline$1.87
-3.11% today
1Y Change
-0.53%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sera Prognostics, Inc. (SERA) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $1.87 and down 0.5% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +5.2%, EPS growth of +32.3%, a dividend yield of 0.0%. What stands out right now is revenue +5.2%, EPS +32.3%, free cash flow -72.3% with operating margin -45066.7% and ROIC -47.0%. Valuation already assumes a fairly strong business story at price/sales 900.6. Stock Foundry combines SERA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SERA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SERA Max Drawdown
-61.12%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SERA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$82.0K
-69.4% YoY
FY Net Income
-$35.0M
+20.8% YoY
Free Cash Flow
-$32.9M
+7.0% YoY
Revenue Growth
+5.2%
EPS Growth
+32.3%
Gross Margin
-102.5%
Net Margin
-39417.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 81K | 77K | 306K | 268K | 82K |
| Gross Profit | -83K | -5K | 96K | 75K | 45K |
| Operating Income | -37M | -37M | -40M | -46M | -35M |
| EBITDA | -36M | -32M | -35M | -43M | -34M |
| Net Income | -32M | -33M | -36M | -44M | -35M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4M | 4M | 4M | 30M | 59M |
| Total Assets | 102M | 73M | 95M | 116M | 147M |
| Total Liabilities | 27M | 25M | 25M | 17M | 8M |
| Shareholder Equity | 75M | 48M | 70M | 99M | 139M |
| Total Debt | 2M | 840K | 2M | 3M | 128K |
| Net Debt | -2M | -3M | -2M | -27M | -59M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
32M
+8.6% YoY
Capital Expenditures
1M
-64.9% YoY
Free Cash Flow
33M
+7.0% YoY
Key ratios
Gross Margin
-102.5%
Operating Margin
-45066.7%
Net Margin
-39417.3%
ROE
-37.5%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.